The discovery of angiotensin-converting enzyme 2 (ACE2) in 2000 is an important event in
the renin-angiotensin system (RAS) story. This enzyme, an homolog of ACE, hydrolyzes …

Angiotensin-converting enzyme 2 (ACE2), a recently identified human homolog of ACE, is a
novel metallocarboxypeptidase with specificity, tissue distribution, and function distinct from …

Angiotensin‐converting enzyme 2 (ACE2) shares some homology with angiotensin‐
converting enzyme (ACE) but is not inhibited by ACE inhibitors. The main role of ACE2 is the …

ACE2 is confined to the endothelium, 10 but further studies showed ACE2 expression in
cardiomyocytes, 17 in the kidney on the luminal surface of tubular epithelial cells, 10, 18 and …

The renin-angiotensin system (RAS) is currently considered a central regulator of blood
pressure in the mammalian organism. Even though renin was first described in 1898, it was …

Components of the renin–angiotensin system are well established targets for
pharmacological intervention in a variety of disorders. Many such therapies abrogate the …

Angiotensin-converting enzyme 2 (ACE2) is the first human homologue of ACE to be
described. ACE2 is a type I integral membrane protein that functions as a carboxypeptidase …

The renin‐angiotensin system (RAS) is a critical regulator of hypertension, primarily through
the actions of the vasoactive peptide Ang II, which is generated by the action of angiotensin …

A novel assay was developed for evaluation of mouse angiotensin-converting enzyme
(ACE) 2 and recombinant human ACE2 (rACE2) activity. Using surface-enhanced laser …

A novel angiotensin-converting enzyme (ACE) homolog, named ACE2, is a
monocarboxypeptidase which metabolizes several peptides. ACE2 degrades Angiotensin …